Laboratorios Richmond SACIF
BCBA:RICH
Laboratorios Richmond SACIF
Research & Development
Laboratorios Richmond SACIF
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Laboratorios Richmond SACIF
BCBA:RICH
|
Research & Development
-1.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Laboratorios Richmond SACIF
Glance View
Laboratorios Richmond SACIF manufactures pharmaceutical products. The company is headquartered in Buenos Aires, Buenos Aires. The company went IPO on 2017-12-22. The firm's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
See Also
What is Laboratorios Richmond SACIF's Research & Development?
Research & Development
-1.8B
ARS
Based on the financial report for Sep 30, 2025, Laboratorios Richmond SACIF's Research & Development amounts to -1.8B ARS.
What is Laboratorios Richmond SACIF's Research & Development growth rate?
Research & Development CAGR 1Y
-178%
Over the last year, the Research & Development growth was -178%.
